Latest Content

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Elevated levels of a combined biomarker integrating CRP, triglycerides, and glucose are associated with increased risk of rheumatoid arthritis.

In real-world usage, 97% of cases of cytokine release syndrome following treatment with lisocabtagene maraleucel happened within 15 days of infusion.

Ryan Haumschild, PharmD, discusses overcoming barriers to cancer care access, emphasizing the role of pharmacy in improving access and affordability.

Pretransplant NPM1 MRD testing significantly predicts relapse risk in acute myeloid leukemia.

ATTRibute-CM data show acoramidis reduced mortality in ATTRwt-CM and ATTRv-CM and raised serum transthyretin through 42 months.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.

Phase 3 OCEANIC-STROKE data show how asundexian offers a potential new secondary stroke prevention option.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.